Journals
Publish with us
Publishing partnerships
About us
Blog
Sarcoma
Journal overview
For authors
For reviewers
For editors
Table of Contents
Special Issues
Sarcoma
/
2018
/
Article
/
Tab 1
/
Review Article
Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy
Table 1
Clinical trials of intratumoral viral vector therapy in soft tissue sarcoma.
Agent
N
Results
Ref.
TNFerade
14
Of 13 evaluable patients, 11 (85%) objective or pathological tumor responses (2 CR and 9 PR), 1 SD
[
60
]
ONYX-015 (+mitomycin-C, doxorubicin, cisplatin)
6
ONYX-015 viral DNA detected in 2 patient biopsies and 5 patient plasma after treatment
[
61
]
Ad5/3-D24-GMCSF
15
2 minor responses, 6 SD, and 4 PD in 12 evaluable patients; median survival time after treatment was 170 days. One patient was alive at 1459 days
[
62
]
HSV1716
9
Four of 5 patients evaluated at day +14 had stable disease by cross-sectional imaging. Three of 7 patients evaluated at day +28 had stable disease, and one of these patients had a decrease in PET standardized uptake values
[
63
]